Rachid Baz, MD

Articles

Dr Baz on AE Management Discussions in Multiple Myeloma

March 29th 2024

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.

Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple Myeloma

February 16th 2024

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Dr Baz on the Background of the KarMMa-3 Trial in Relapsed/Refractory Multiple Myeloma

January 9th 2024

Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in triple-class–exposed, relapsed/refractory multiple myeloma.

Dr. Baz on the Role of Alkylating Agents in Relapsed/Refractory Multiple Myeloma

October 5th 2021

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

Dr. Baz on the Utility of Venetoclax in Heavily Pretreated Multiple Myeloma

September 29th 2021

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

Dr. Baz on Selinexor in Multiple Myeloma

September 5th 2018

Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.

Dr. Baz on Varying Treatment Approaches for Patients With Multiple Myeloma

May 26th 2017

Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.